Nick Morrell
@NickMorrell15
Followers
1K
Following
8K
Media
29
Statuses
847
Clinician scientist, lung doc, co-Founder of Morphogen-IX and Interact Bio Ltd, developing better treatments for pulmonary arterial hypertension.
Cambridge, UK
Joined June 2018
ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport . Great to see this out. Wonderful collaboration with @PeterVangheluwe and team!.
academic.oup.com
AbstractAims. Potential loss-of-function variants of ATP13A3, the gene encoding a P5B-type transport ATPase of undefined function, were recently identified
0
3
13
RT @charlot_summers: We have had lots of fun this morning celebrating the announcement of a £16 million gift to HLRI and are thrilled to ch….
0
8
0
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
388
671
3K
RT @HLRI_Cambridge: We are delighted to announce that today we have become the Victor Phillip Dahdaleh Heart & Lung Research Institute to h….
0
17
0
RT @centessa: Join Centessa and the Rare Disease community to help raise awareness of #RareDisease. Show your stripes in honor of #RareDise….
0
2
0
RT @mark_toshner: A lifetime pleasure to give a plenary talk at my home conference #winterBTS2022.
0
3
0
RT @centessa: Centessa hosted @PHAssociation & individuals living with PH for an event to raise awareness of this complex disease. Learn ho….
0
3
0
RT @AinscoughAlex: Proud moment! My First, First Author paper is finally published! Happy Monday News! 🥳. An organ-on-chip model of pulmona….
nature.com
Communications Biology - A biomimetic inducible model of pulmonary arterial hypertension (PAH) is presented, combining natural and induced BMPR2 dysfunction with hypoxia in lung endothelial cells...
0
26
0
RT @TBX4_Life: Amazing Accomplishment: our first joint paper is published in Blue Journal @ATSBlueEditor !! Huge Thanks to all contributors….
0
5
0
RT @centessa: Today we announced that new data from an additional 18-months of continued treatment with SerpinPC from the OLE of our Phase….
0
5
0
RT @centessa: It's #PulmonaryHypertension Awareness Month. Centessa's advancing MGX292 as part of our mission to develop transformational m….
0
3
0
RT @Montanidavid: Great job of the International Consortium for Genetic Studies in PAH. Proud to be part of this dynamic team. @Pulmotensio….
0
17
0
RT @sciencescanner: Fantastic to see @RxCelerate Founder and CEO, Jill Reckless, featured in Sunday Times!. Jill h….
0
3
0
RT @centessa: Today we announced a poster presentation of data from our oral small-molecule orexin receptor 2 (OX2R) agonist discovery pipe….
investors.centessa.com
– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) – – Company recognizes World Narcolepsy Day on September 22 nd – BOSTON and...
0
9
0
RT @centessa: Thrilled to announce that US Orphan Drug designation was granted to SerpinPC, our novel inhibitor of activated protein C, bei….
0
5
0
RT @Finlay_Jonny: LockBody is hiring! Looking for talented, passionate scientists who want to change the future of cancer therapy: https://….
0
1
0
RT @iCharmaine: Today is a historic day for @TheBHF, as we announce #CureHeart as the winner of our £30m #BigBeatChallenge 🔬. I'm unbelieva….
0
24
0
The peppered moth - never actually seen one in real life before (although this one sadly dead). One of the first evolutionary stories we heard at school featured this beautiful creature.
1
0
11
RT @MuruLago: Our TBX4 paper has just been accepted for publication in @ATSBlueEditor !!. Happy of having shared this scientific journey wi….
0
2
0
Honoured to host HRH Duchess of Gloucester at our official opening of the Cambridge Heart and Lung Research Institute yesterday. Now the real work begins to undertake high impact translational science to benefit patients with cardiopulmonary conditions! @BHF @RoyalPapworth
5
17
124